Fagron Sa · EURONEXT:FAGR
Fagron Sa — Fagron Sa Ord — Q1 2021 Earnings Presentation
13 slides from Fagron Sa's earnings presentation, Apr 13, 2021
Slide 1: Fagron Q1-2021 Trading Update
Fagron Q1-2021 Trading Update Rafael Padilla, CEO Karin de Jong, CFO April 13, 2021 Together we create the future of personalizing medicine ⚫
Slide 2: Fagron Team
Fagron Team Rafael Padilla Karin de Jong Constantijn van Rietschoten Chief Executive Officer Chief Financial Officer Chief Corp. Affairs Officer Started in 2002 Started in 2008 Started in 2008 Pg.2
Slide 3: Consolidated Turnover
Consolidated Turnover (x € 1,000) Q1-2021 Q1-2020 Total growth Total growth CER Turnover 134,777 141,621 -4.8% +4.9% • Turnover down 4.8% (+4.9% CER) • Organic growth of 2.6% CER Regions* Segments* 28.3% 29.5% 46.8% 50.3% 19.6% 23.7% EMEA Latin America North America Essentials Brands FCS Pg.3 * Base
Slide 4: Turnover Development
Turnover Development Q1-2021 compared to Q1-2020 150 140 13.6 141.6 7.2 7.2 130 3.7 134.8 3.1 120 110 100 90 80 Pg.4
Slide 5: Q1-2021 Results per Area
Q1-2021 Results per Area New GMP-Repackaging Facility in Poland Transition to start in second half of April 2021
Slide 6: Geographical Breakdown
Geographical Breakdown €63.1m -7.3% (-6.7%) €39.8m +1.0% (+10.4%) €31.9m -6.7% (+21.3%) Pg.6
Slide 7: Fagron EMEA
Fagron EMEA (x € 1,000) Q1-2021 Q1-2020 Total growth Total growth CER Turnover 63,110 68,074 -7.3% -6.7% • Organic turnover growth of -10.6% CER • Strong decline in prescriptions due to lockdowns and other restrictive measures negatively impacted demand for Essentials and non-sterile Compounding Ser
Slide 8: Dutch Market: Average Number of Prescriptions per Month
Dutch Market: Average Number of Prescriptions (first issue) per Month Source: KNMP Monitor Coronavirus; 9 March 2021 – download here GP Specialist GP Specialist GP Specialist 2019 2019 2020 2020 2021 2021 Pg.8
Slide 9: Fagron Latin America
Fagron Latin America (x € 1,000) Q1-2021 Q1-2020 Total growth Total growth CER Turnover 31,890 34,176 -6.7% +21.3% • Turnover decline due to sharp weakening of BRL and MXN versus EUR • Organic turnover growth of 21.0% CER • Strengthening market leadership with strong turnover growth in Essentials (+
Slide 10: Fagron North America
Fagron North America (x € 1,000) Q1-2021 Q1-2020 Total growth Total growth CER Turnover 39,777 39,371 +1.0% +10.4% • Turnover growth impacted by weakening of USD vs. EUR • Organic turnover growth of 9.4% CER • Brands & Essentials (+7.9% CER) • FSS in Wichita (+15.3% CER) • Run rate of USD 60m in Mar
Slide 11: 2021 Expectations
2021 Expectations • Further growth in turnover and profitability • Streamlining EMEA-region • Leveraging customers & SKUs at FSS US • Strong R&D-pipeline • Products aimed at prevention • Sterile compounds, incl. IV-bags • Global roll-out of Fagron Genomics • Active and disciplined acquisition strate
Slide 12: Q&A
Q&A Pg.12
Slide 13: Slide 13